With BG's excellent biosafety profile and US's clinical approval, this dual‐gating strategy offers a safe and efficient method for the precise treatment of cancers with high TRPV2 expression, providing new insights into the design of calcium‐overload‐based cancer therapies. This evidence concerns the gene TRPV2 and cancer.